The Scientist interviewed clinical pharmacologist Clara Locher, coauthor of a new survey aimed at detecting editorial bias, regarding her team’s findings about biomedical publishing.
An analysis finds that reviewers are more likely to choose to be de-anonymized when their reviews are positive, suggesting instituting a fully open process might discourage negative feedback.
Zhangfeng Hu will be unable to submit manuscripts for three years after having violated the journal’s policy about making study materials available to other scientists.
The editor-in-chief will step down this month following the release of a podcast in February that suggested systemic racism does not exist in medicine.
The issue’s guest editors resign after falling out with the publisher over the management of papers, including a rejected manuscript on ivermectin, that were submitted for a special issue on drug repurposing for COVID-19.
The agreement will enable authors at eligible German institutes to publish an estimated 400 open-access papers each year in Springer Nature journals from the Nature line of titles.
The scholarly publisher has announced several new licensing agreements in both Europe and the US—but some major academic groups are still without contracts and access to journals.